242 related articles for article (PubMed ID: 29706950)
1. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
Front Immunol; 2018; 9():542. PubMed ID: 29706950
[TBL] [Abstract][Full Text] [Related]
2. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
Nishie W
Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
Sun L; Wang C; Wu C; Zhou Y; Wang C
Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
Kridin K
Dermatol Ther; 2020 Jul; 33(4):e13790. PubMed ID: 32506731
[TBL] [Abstract][Full Text] [Related]
7. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid.
Suezawa M; Dainichi T; Kaku Y; Izumi M; Kataoka K; Ishii N; Koga H; Izumi K; Nishie W
J Dermatol; 2021 Oct; 48(10):1584-1587. PubMed ID: 34265108
[TBL] [Abstract][Full Text] [Related]
9. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Tasanen K; Varpuluoma O; Nishie W
Front Immunol; 2019; 10():1238. PubMed ID: 31275298
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
Maki N; Nishie W; Takazawa M; Kakurai M; Yamada T; Umemoto N; Kawase M; Izumi K; Shimizu H; Demitsu T
J Dermatol; 2018 May; 45(5):600-602. PubMed ID: 29446164
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
Front Immunol; 2022; 13():843480. PubMed ID: 35309321
[TBL] [Abstract][Full Text] [Related]
13. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
[TBL] [Abstract][Full Text] [Related]
14. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
[TBL] [Abstract][Full Text] [Related]
15. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus.
Chanprapaph K; Pratumchart N; Limtong P; Rutnin S; Sukasem C; Kungvalpivat P; Triamchaisri S; Suchonwanit P
J Dermatol; 2021 Apr; 48(4):486-496. PubMed ID: 33543537
[TBL] [Abstract][Full Text] [Related]
17. Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
Nieto-Benito LM; Bergón-Sendín M; Pulido-Pérez A; Rosell-Díaz ÁM; Parra-Blanco V; Suárez-Fernández R
Exp Dermatol; 2021 Sep; 30(9):1345-1351. PubMed ID: 34028898
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.
Tuusa J; Kokkonen N; Mattila A; Huilaja L; Varpuluoma O; Rannikko S; Glumoff V; Miettunen J; Tasanen K
J Invest Dermatol; 2023 Jan; 143(1):78-86.e12. PubMed ID: 35921900
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis.
Hung CT; Chang YL; Wang WM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430582
[TBL] [Abstract][Full Text] [Related]
20. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]